DBV Technologies S.A. Price & Performance (DBVT)

DBV Technologies presented compelling five-year results from its PEOPLE study at the AAAAI/WAO Joint Congress. The VIASKIN Peanut patch showed a responder increase from 39.1% to 73.3% over 60 months, highlighting its potential as a breakthrough treatment for children with peanut allergies. Long-term safety and compliance were also emphasized.123

DBV Technologies' stock rose 14% last week, though it remains 80% lower over five years. Analysts attribute the gains to growing optimism around its peanut allergy treatment, despite challenges like declining revenues and cash burn. The upcoming VITESSE trial results are seen as a pivotal moment for the company's future.456

The VITESSE trial, the largest peanut allergy study for children, is expected to release data in late 2025. Analysts highlight its importance for regulatory approval and market entry. DBV's financial position remains stable for now, but funding beyond Q1 2025 will be critical to support its clinical and commercialization efforts.789